Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Leap Therapeutics Q4 EPS $(0.46) Beats $(0.55) Estimate, Cash Balance of $70.6M

Author: Benzinga Newsdesk | March 18, 2024 07:19am
Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 58.18 percent increase over losses of $(1.10) per share from the same period last year.

Posted In: LPTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist